GEN News Highlights

AstraZeneca, MTPC Partner to Validate Diabetic Nephropathy Targets

(Page
1
of
1)

AstraZeneca and Mitsubishi Tanabe Pharma (MTPC) entered a three-year research collaboration in the area of diabetic nephropathy to validate research targets and molecules.

Spanning from target selection up to the delivery of small molecule candidate drugs, the collaboration will include targets from each company’s early research portfolios that have been identified as approaches of common interest. Additional targets may be included under the collaboration at a later stage. The research will be performed in parallel at AstraZeneca’s Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Mölndal, Sweden, and at MTPC’s facilities in Japan. The companies said they believe the alliance will yield high-quality candidate drugs much faster than working alone. There is no financial commitment and each organization will contribute equal resources.

“The collaboration will allow us to focus on early stage programs and generate decision-making data faster than working alone, ultimately providing a quicker expansion of our diabetic nephropathy portfolio for the treatment of chronic kidney disease,” said Marcus Schindler, head of CVMD innovative medicines unit at AstraZeneca.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.